c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M

Cancer Research

Volumn 71, Issue 22, 2011, Pages 6930-6939

  Kan, Charlene E ^a   Cipriano, Rocky ^a   Jackson, Mark W ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; ONCOSTATIN M; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; SHORT HAIRPIN RNA; STAT3 PROTEIN;

ARTICLE; BREAST EPITHELIUM; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; METASTASIS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HUMANS; INTERLEUKIN-6; MAMMARY GLANDS, HUMAN; NEOPLASM PROTEINS; ONCOSTATIN M; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81155132204     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3860     Document Type: Article

References (44)

1. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003;5:31-6. (Pubitemid 36553576)
2. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006;1:119-50.
3. Tanaka M, Miyajima A, Oncostatin M. A multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003;149:39-52.
4. Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol 2010;88:1145-56.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
6. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011;19:429-31.
7. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004;202: 41-9. (Pubitemid 38072844)
8. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 1986;83:9739-43. (Pubitemid 17223432)
9. Lindberg RA, Juan TS, Welcher AA, Sun Y, Cupples R, Guthrie B, et al. Cloning and characterization of a specific receptor for mouse oncostatin M. Mol Cell Biol 1998;18:3357-67. (Pubitemid 28240508)
10. Spence MJ, Vestal RE, Liu J. Oncostatin M-mediated transcriptional suppression of the c-myc gene in breast cancer cells. Cancer Res 1997;57:2223-8. (Pubitemid 27247042)
11. Zhang F, Li C, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 2003;22:894-905. (Pubitemid 36255825)
12. Jorcyk CL, Holzer RG, Ryan RE. OncostatinMinduces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine 2006;33:323-36. (Pubitemid 43948887)
13. Loewen GM, Tracy E, Blanchard F, Tan D, Yu J, Raza S, et al. Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer 2005;5:145.
14. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-7. (Pubitemid 44864442)
15. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007;21:43-8. (Pubitemid 46089705)
16. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
17. Garbe JC, Bhattacharya S, Merchant B, Bassett E, SwisshelmK, Feiler HS, et al. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res 2009;69:7557-68.
18. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47. (Pubitemid 40216455)
19. Wu D, Chen B, Parihar K, He L, Fan C, Zhang J, et al. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 2006;25:1153-64.
20. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006;116:3171-82. (Pubitemid 44878631)
21. Kan CE, Patton JT, Stark GR, Jackson MW. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. Cancer Res 2007;67:9862-8. (Pubitemid 47621234)
22. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-76.
23. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998;17:199-205. (Pubitemid 28371893)
24. Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M, Jackson MW. TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci U S A 2011;108:8668-73.
25. Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clin Exp Metastasis 2004;21:167-76. (Pubitemid 38988090)
26. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003;4:1169-76. (Pubitemid 37540685)
27. Yagil Z, Nechushtan H, Kay G, Yang CM, Kemeny DM, Razin E. The enigma of the role of protein inhibitor of activated STAT3 (PIAS3) in the immune response. Trends Immunol 2010;31:199-204.
28. Kim DJ, Chan KS, Sano S, Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 2007;6:725-31. (Pubitemid 47255194)
29. Jamerson MH, Johnson MD, Dickson RB. Of mice and Myc: c-Myc and mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2004; 9:27-37. (Pubitemid 39137495)
30. Liao DJ, Dickson RB. c-Myc in breast cancer, Endocr. Relat Cancer 2000;7:143-64.
31. Cipriano R, Jackson MW. Delineating oncogene/tumor suppressor interactions in human mammary epithelial cells. Cell Cycle 2011;10: 2612-3.
32. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004;3:327-44. (Pubitemid 38702087)
33. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27. (Pubitemid 351655218)
34. Cichon MA, Degnim AC, Visscher DW, Radisky DC. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia 2010;15: 389-97.
35. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005;65:8896-904. (Pubitemid 41377379)
36. Tran TA, Ross JS, Sheehan CE, Carlson JA. Comparison of oncostatin Mexpression in keratoacanthoma and squamous cell carcinoma. Mod Pathol 2000;13:427-32. (Pubitemid 30225232)
37. Ng G, Winder D, Muralidhar B, Gooding E, Roberts I, Pett M, et al. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J Pathol 2007;212:325-34. (Pubitemid 47010066)
38. Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ, et al. Coexpression of oncostatinMand its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine 2002;17:324-34.
39. Singh RA, Sodhi A. Cisplatin-treated macrophages produce oncostatin M: regulation by serine/threonine and protein tyrosine kinases/ phosphatases and Ca2+/calmodulin. Immunol Lett 1998;62:159-64. (Pubitemid 28365870)
40. Sodhi A, Shishodia S, Shrivastava A. Cisplatin-stimulated murine bone marrow-derived macrophages secrete oncostatin M. Immunol Cell Biol 1997;75:492-6. (Pubitemid 27508990)
41. Grant SL, Douglas AM, Goss GA, Begley CG. Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors 2001;19:153-62. (Pubitemid 34065697)
42. Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, et al. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes. J Pathol 2008;216: 451-9.
43. Clark CJ, Whang S, Paige KT. Incidence of precancerous lesions in breast reduction tissue: a pathologic review of 562 consecutive patients. Plast Reconstr Surg 2009;124:1033-9.
44. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005;118:3573-84.